Skip to main content
Top
Published in: Endocrine 2/2019

01-02-2019 | Original Article

Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial

Authors: Vicente Corrêa Júnior, Flávio Danni Fuchs, Beatriz D. Schaan, Leila Beltrami Moreira, Sandra Costa Fuchs, Miguel Gus

Published in: Endocrine | Issue 2/2019

Login to get access

Abstract

Objective

Part of the beneficial effects of metformin on the prevention of cardiovascular events in diabetes can be attributed to pleiotropic effects, including a blood pressure (BP)-lowering effect. In a double-blind parallel clinical trial (NCT02072382), the effect of metformin on BP evaluated by ambulatory blood pressure monitoring (ABPM) was measured.

Methods

Ninety-seven patients with hypertension, but without diabetes mellitus, were randomized to receive 850–1700 mg of metformin (n = 48) or placebo (n = 49). Clinical, laboratory, and ABPM data were collected at the baseline and after 8 weeks of follow-up.

Results

The sample consisted mainly of White overweight women. There was no difference in BP reduction measured by ABPM between both groups. There was no effect in BP measured in the different periods of ABP monitoring and office BP. Additionally, fasting plasma glucose, lipids, and C-reactive protein remained unchanged during the trial. There was a significant reduction in waist circumference with metformin (95.1 ± 10.4 to 89.3 ± 27.4 cm; p = 0.02).

Conclusion

In the present trial, metformin did not reduce BP, measured by ABP monitoring, in hypertensive patients without diabetes.
Literature
1.
2.
go back to reference W.B. Kannel, D.L. McGee, Diabetes and cardiovascular disease. The Framingham Study. JAMA 241, 2035–2038 (1979)CrossRefPubMed W.B. Kannel, D.L. McGee, Diabetes and cardiovascular disease. The Framingham Study. JAMA 241, 2035–2038 (1979)CrossRefPubMed
3.
go back to reference C.S. Fox, S. Coady, P.D. Sorlie, R.B. D’Agostino, M.J. Pencina, R.S. Vasan, J.B. Meigs, D. Levy, P.J. Savage, Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115(12), 1544–1550 (2007)CrossRefPubMed C.S. Fox, S. Coady, P.D. Sorlie, R.B. D’Agostino, M.J. Pencina, R.S. Vasan, J.B. Meigs, D. Levy, P.J. Savage, Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115(12), 1544–1550 (2007)CrossRefPubMed
4.
go back to reference R.A. Hayward, P.D. Reaven, W.L. Wiitala, G.D. Bahn, D.J. Reda, L. Ge, M. McCarren, W.C. Duckworth, N.V. Emanuele, VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 372(23), 2197–2206 (2015)CrossRefPubMed R.A. Hayward, P.D. Reaven, W.L. Wiitala, G.D. Bahn, D.J. Reda, L. Ge, M. McCarren, W.C. Duckworth, N.V. Emanuele, VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 372(23), 2197–2206 (2015)CrossRefPubMed
5.
go back to reference UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317, 703–713 (1998)CrossRefPubMedCentral UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317, 703–713 (1998)CrossRefPubMedCentral
6.
go back to reference Evidence-Based Guideline for the Management of High Blood Pressure in Adults, Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5), 507–520 (2014)CrossRef Evidence-Based Guideline for the Management of High Blood Pressure in Adults, Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5), 507–520 (2014)CrossRef
7.
go back to reference UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998)CrossRef UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998)CrossRef
8.
go back to reference C. Lamanna, M. Monami, E. Mannucci, Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 13, 221–228 (2011)CrossRefPubMed C. Lamanna, M. Monami, E. Mannucci, Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 13, 221–228 (2011)CrossRefPubMed
9.
go back to reference B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)CrossRefPubMed B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)CrossRefPubMed
10.
go back to reference A.K. Madiraju, D.M. Erion, Y. Rahimi, X.M. Zhang, D.T. Braddock, R.A. Albright, B.J. Prigaro, J.L. Wood, S. Bhanot, M.J. MacDonald, M. Jurczak, J.P. Camporez, H.Y. Lee, G.W. Cline, V.T. Samuel, R.G. Kibbey, G.I. Shulman, Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546 (2014)CrossRefPubMedPubMedCentral A.K. Madiraju, D.M. Erion, Y. Rahimi, X.M. Zhang, D.T. Braddock, R.A. Albright, B.J. Prigaro, J.L. Wood, S. Bhanot, M.J. MacDonald, M. Jurczak, J.P. Camporez, H.Y. Lee, G.W. Cline, V.T. Samuel, R.G. Kibbey, G.I. Shulman, Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546 (2014)CrossRefPubMedPubMedCentral
11.
go back to reference I. Kosegawa, S. Katayama, C. Kikuchi, H. Kashiwabara, K. Negishi, J. Ishii, Y. Oka, Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. Hypertens. Res. 19, 37–41 (1996)CrossRefPubMed I. Kosegawa, S. Katayama, C. Kikuchi, H. Kashiwabara, K. Negishi, J. Ishii, Y. Oka, Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. Hypertens. Res. 19, 37–41 (1996)CrossRefPubMed
12.
go back to reference R.C. Bhalla, K.F. Toth, E. Tan, R.A. Bhatty, E. Mathias, R.V. Sharma, Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am. J. Hypertens. 9, 570–576 (1996)CrossRefPubMed R.C. Bhalla, K.F. Toth, E. Tan, R.A. Bhatty, E. Mathias, R.V. Sharma, Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am. J. Hypertens. 9, 570–576 (1996)CrossRefPubMed
13.
go back to reference M.S. Muntzel, I. Hamidou, S. Barrett, Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. Hypertension 33, 1135–1140 (1999)CrossRefPubMed M.S. Muntzel, I. Hamidou, S. Barrett, Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. Hypertension 33, 1135–1140 (1999)CrossRefPubMed
14.
go back to reference M.S. Muntzel, A. Abe, J.S. Petersen, Effects of adrenergic, cholinergic and ganglionic blockade on acute depressor responses to metformin in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 281, 618–623 (1997)PubMed M.S. Muntzel, A. Abe, J.S. Petersen, Effects of adrenergic, cholinergic and ganglionic blockade on acute depressor responses to metformin in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 281, 618–623 (1997)PubMed
15.
go back to reference D. Kirpichnikov, S.I. McFarlane, J.R. Sowers, Metformin: an update. Ann. Intern. Med. 137, 25–33 (2002)CrossRefPubMed D. Kirpichnikov, S.I. McFarlane, J.R. Sowers, Metformin: an update. Ann. Intern. Med. 137, 25–33 (2002)CrossRefPubMed
16.
go back to reference D.K. Nagi, J.S. Yudkin, Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16, 621–629 (1993)CrossRefPubMed D.K. Nagi, J.S. Yudkin, Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16, 621–629 (1993)CrossRefPubMed
17.
go back to reference J.C.N. Chan, B. Tomlinson, Critchley JAJH, C.S. Cockram, R.J. Walden, Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 16, 1035–1038 (1993)CrossRefPubMed J.C.N. Chan, B. Tomlinson, Critchley JAJH, C.S. Cockram, R.J. Walden, Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 16, 1035–1038 (1993)CrossRefPubMed
18.
go back to reference D. Giugliano, N. De Rosa, G. Di Maro, R. Marfella, R. Acampora, R. Buoniconti, F. D’Onofrio, Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16, 1387–1390 (1993)CrossRefPubMed D. Giugliano, N. De Rosa, G. Di Maro, R. Marfella, R. Acampora, R. Buoniconti, F. D’Onofrio, Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16, 1387–1390 (1993)CrossRefPubMed
19.
go back to reference K. Landin, L. Tengborn, U. Smith, Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J. Intern. Med. 229, 181–187 (1991)CrossRefPubMed K. Landin, L. Tengborn, U. Smith, Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J. Intern. Med. 229, 181–187 (1991)CrossRefPubMed
20.
go back to reference D. Giugliano, A. Quatraro, G. Consoli, A. Minei, A. Ceriello, N. De Rosa, F. D’Onofrio, Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur. J. Clin. Pharmacol. 44, 107–112 (1993)CrossRefPubMed D. Giugliano, A. Quatraro, G. Consoli, A. Minei, A. Ceriello, N. De Rosa, F. D’Onofrio, Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur. J. Clin. Pharmacol. 44, 107–112 (1993)CrossRefPubMed
21.
go back to reference L.W. Campbell, C. Duncan, N.W. Patton, T. Broadhead, G.T. Tucker, H.F. Woods, The effect of metformin on Glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus. Diabet. Med. 4, 337–341 (1987)CrossRefPubMed L.W. Campbell, C. Duncan, N.W. Patton, T. Broadhead, G.T. Tucker, H.F. Woods, The effect of metformin on Glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus. Diabet. Med. 4, 337–341 (1987)CrossRefPubMed
22.
go back to reference S. Gudbjörnsdottir, P. Friberg, M. Elam, S. Attvall, P. Lönnroth, G. Wallin, The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood Press. 3, 394–403 (1994)CrossRefPubMed S. Gudbjörnsdottir, P. Friberg, M. Elam, S. Attvall, P. Lönnroth, G. Wallin, The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood Press. 3, 394–403 (1994)CrossRefPubMed
23.
go back to reference C.A. Mourão Júnior, J.R. Sá, O.M. Guedes, S.A. Dib, Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin. Braz. J. Med. Biol. Res. 39, 489–494 (2006)CrossRefPubMed C.A. Mourão Júnior, J.R. Sá, O.M. Guedes, S.A. Dib, Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin. Braz. J. Med. Biol. Res. 39, 489–494 (2006)CrossRefPubMed
24.
go back to reference A. Kooy, J. Jager, P. Lehert, D. Bets, M.G. Wulffele, A.J.M. Donker, C.D.A. Stehouwer, Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169(6), 616–625 (2009)CrossRefPubMed A. Kooy, J. Jager, P. Lehert, D. Bets, M.G. Wulffele, A.J.M. Donker, C.D.A. Stehouwer, Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169(6), 616–625 (2009)CrossRefPubMed
25.
go back to reference O. Snorgaard, L. Kober, J. Carlsen, The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J. Intern. Med. 242, 407–412 (1997)CrossRefPubMed O. Snorgaard, L. Kober, J. Carlsen, The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J. Intern. Med. 242, 407–412 (1997)CrossRefPubMed
26.
go back to reference W.T. Friedewald, R.I. Levy, D.S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972)PubMed W.T. Friedewald, R.I. Levy, D.S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972)PubMed
27.
go back to reference K.G. Alberti, P. Zimmet, J. Shaw, Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 23(5), 469–480 (2006)CrossRefPubMed K.G. Alberti, P. Zimmet, J. Shaw, Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 23(5), 469–480 (2006)CrossRefPubMed
28.
go back to reference M.V.B. Malachias, R.J. Franco, C.L.M. Forjaz, A.M.G. Pierin, M.M. Gowdak, M.R.S.T. Klein, V. Mtsudo. VI Diretrizes Brasileiras de Hipertensão. Arq. Bras. Cardiol. 95(1 supl.1), 1–51 (2010) M.V.B. Malachias, R.J. Franco, C.L.M. Forjaz, A.M.G. Pierin, M.M. Gowdak, M.R.S.T. Klein, V. Mtsudo. VI Diretrizes Brasileiras de Hipertensão. Arq. Bras. Cardiol. 95(1 supl.1), 1–51 (2010)
29.
go back to reference G. Riegel, L.B. Moreira, S.C. Fuchs, M. Gus, G. Nunes, V. Correa Jr, M. Wiehe, C.C. Gonçalves, F.S. Fernandes, F.D. Fuchs, Long-term effectiveness of non-drug recommendations to treat hypertension in a clinical setting. Am. J. Hypertens. 25, 1202–1208 (2012)CrossRefPubMed G. Riegel, L.B. Moreira, S.C. Fuchs, M. Gus, G. Nunes, V. Correa Jr, M. Wiehe, C.C. Gonçalves, F.S. Fernandes, F.D. Fuchs, Long-term effectiveness of non-drug recommendations to treat hypertension in a clinical setting. Am. J. Hypertens. 25, 1202–1208 (2012)CrossRefPubMed
30.
go back to reference M.G. Wulffelé, A. Kooy, D. De Zeeuw, C.D.A. Stehouwer, R.T. Gansevoort, The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J. Intern. Med. 256, 1–14 (2004)CrossRefPubMed M.G. Wulffelé, A. Kooy, D. De Zeeuw, C.D.A. Stehouwer, R.T. Gansevoort, The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J. Intern. Med. 256, 1–14 (2004)CrossRefPubMed
31.
go back to reference L. Zhou, H. Liu, X. Wen, Y. Peng, Y. Tian, L. Zhao, Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials. J. Hypertens. 35, 18–26 (2017)CrossRefPubMed L. Zhou, H. Liu, X. Wen, Y. Peng, Y. Tian, L. Zhao, Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials. J. Hypertens. 35, 18–26 (2017)CrossRefPubMed
32.
go back to reference C. Thomopoulos, G. Katsimagklis, T. Makris, Metformin and blood pressure lowering: a questioned association. J. Hypertens. 35, 27–28 (2017)CrossRefPubMed C. Thomopoulos, G. Katsimagklis, T. Makris, Metformin and blood pressure lowering: a questioned association. J. Hypertens. 35, 27–28 (2017)CrossRefPubMed
33.
go back to reference J.R. Ussher, D.L. Drucker, Cardiovascular actions of incretin-based therapies. Circ. Res. 114, 1788–1803 (2014)CrossRefPubMed J.R. Ussher, D.L. Drucker, Cardiovascular actions of incretin-based therapies. Circ. Res. 114, 1788–1803 (2014)CrossRefPubMed
34.
go back to reference S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse, LEADER Steering Committee on behalf of the LEADER Trial Investigators. N. Engl. J. Med. 375, 311–322 (2016)CrossRefPubMedPubMedCentral S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse, LEADER Steering Committee on behalf of the LEADER Trial Investigators. N. Engl. J. Med. 375, 311–322 (2016)CrossRefPubMedPubMedCentral
35.
go back to reference J.B. Buse, D.J. Drucker, K.L. Taylor, T. Kim, B. Walsh, H. Hu, K. Wilhelm, M. Trautmann, L.Z. Shen, L.E. Porter, Duration-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33, 1255–1261 (2010)CrossRefPubMedPubMedCentral J.B. Buse, D.J. Drucker, K.L. Taylor, T. Kim, B. Walsh, H. Hu, K. Wilhelm, M. Trautmann, L.Z. Shen, L.E. Porter, Duration-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33, 1255–1261 (2010)CrossRefPubMedPubMedCentral
36.
go back to reference R. Krysiak, B. Okopien, Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. Atherosclerosis 225, 403–407 (2012)CrossRefPubMed R. Krysiak, B. Okopien, Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. Atherosclerosis 225, 403–407 (2012)CrossRefPubMed
37.
go back to reference A. Chakraborty, S. Chowdhury, M. Bhattacharyya, Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res. Clin. Pract. 9(3), 56–62 (2011)CrossRef A. Chakraborty, S. Chowdhury, M. Bhattacharyya, Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res. Clin. Pract. 9(3), 56–62 (2011)CrossRef
38.
go back to reference A.D. Pradhan, B.M. Everett, N.R. Cook, N. Rifai, P.M. Ridker, Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 302(11), 1186–1194 (2009)CrossRefPubMed A.D. Pradhan, B.M. Everett, N.R. Cook, N. Rifai, P.M. Ridker, Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 302(11), 1186–1194 (2009)CrossRefPubMed
39.
go back to reference A.E. Caballero, A. Delgado, C.A. Aquilar-Salinas, A.N. Herrera, J.L. Castillo, T. Cabrera, F.J. Gomez-Perez, J.A. Rull, The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 89(8), 3943–3498 (2004)CrossRefPubMed A.E. Caballero, A. Delgado, C.A. Aquilar-Salinas, A.N. Herrera, J.L. Castillo, T. Cabrera, F.J. Gomez-Perez, J.A. Rull, The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 89(8), 3943–3498 (2004)CrossRefPubMed
40.
go back to reference E. Selvin, S. Bolen, H.C. Yeh, C. Wiley, L.M. Wilson, S.S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E.B. Bass, F.L. Brancati, Cardiovascular outcomes in trials of oral diabetes medications. A systematic review. Arch. Intern. Med. 168(19), 2070–2080 (2008)CrossRefPubMedPubMedCentral E. Selvin, S. Bolen, H.C. Yeh, C. Wiley, L.M. Wilson, S.S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E.B. Bass, F.L. Brancati, Cardiovascular outcomes in trials of oral diabetes medications. A systematic review. Arch. Intern. Med. 168(19), 2070–2080 (2008)CrossRefPubMedPubMedCentral
41.
go back to reference K. Fitch, S. Abbara, H. Lee, E. Stavrou, R. Sacks, L. Hemphill, M. Torriani, S. Grinspoon, Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS 26, 587–597 (2012)CrossRefPubMed K. Fitch, S. Abbara, H. Lee, E. Stavrou, R. Sacks, L. Hemphill, M. Torriani, S. Grinspoon, Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS 26, 587–597 (2012)CrossRefPubMed
42.
go back to reference C. Bulcão, F.F. Ribeiro-Filho, A. Sañudo, S.G. Roberta Ferreira, Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am. J. Cardiovasc. Drugs 7(3), 219–224 (2007)CrossRefPubMed C. Bulcão, F.F. Ribeiro-Filho, A. Sañudo, S.G. Roberta Ferreira, Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am. J. Cardiovasc. Drugs 7(3), 219–224 (2007)CrossRefPubMed
43.
go back to reference R. Ladeiras-Lopes, R. Fontes-Carvalho, N. Bettencourt, F. Sampaio, V. Gama, A. Leite-Moreira, Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. Expert Opin. Ther. Targets 19(7), 869–877 (2015)CrossRefPubMed R. Ladeiras-Lopes, R. Fontes-Carvalho, N. Bettencourt, F. Sampaio, V. Gama, A. Leite-Moreira, Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. Expert Opin. Ther. Targets 19(7), 869–877 (2015)CrossRefPubMed
44.
go back to reference D. Preiss, S.M. Lloyd, I. Ford, J.J. McMurray, R.R. Holman, P. Welsh, M. Fisher, C.J. Packard, N. Sattar, Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2, 116–124 (2014)CrossRefPubMed D. Preiss, S.M. Lloyd, I. Ford, J.J. McMurray, R.R. Holman, P. Welsh, M. Fisher, C.J. Packard, N. Sattar, Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2, 116–124 (2014)CrossRefPubMed
45.
go back to reference L.G. Aguiar, L.R. Bahia, N. Villela, C. Laflor, F. Sicuro, N. Wiernsperger, D. Bottino, E. Bouskela, Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 29(5), 1083–1089 (2006)CrossRefPubMed L.G. Aguiar, L.R. Bahia, N. Villela, C. Laflor, F. Sicuro, N. Wiernsperger, D. Bottino, E. Bouskela, Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 29(5), 1083–1089 (2006)CrossRefPubMed
Metadata
Title
Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial
Authors
Vicente Corrêa Júnior
Flávio Danni Fuchs
Beatriz D. Schaan
Leila Beltrami Moreira
Sandra Costa Fuchs
Miguel Gus
Publication date
01-02-2019
Publisher
Springer US
Published in
Endocrine / Issue 2/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1722-1

Other articles of this Issue 2/2019

Endocrine 2/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.